Long-Term In Vivo Therapeutic Protein Production and Vaccine Development for Broadly Neutralizing Antibodies Against Major Pathogens

Scientists have developed a gene-editing approach that enables hematopoietic stem and progenitor cells to function as long-term protein factories, producing therapeutic antibodies and other proteins directly in the body. This method, reported in Science on April 16, 2026, uses small numbers of modified stem cells to achieve sustained, high-level expression of broadly neutralizing antibodies against major pathogens.

The research addresses a persistent challenge in biomedicine: maintaining therapeutic protein levels over extended periods without frequent dosing. Current methods for delivering monoclonal antibodies or vaccines often require repeated administrations and struggle to elicit protective levels of broadly neutralizing antibodies (bNAbs) against viruses like HIV, influenza, and hepatitis C.

By editing hematopoietic stem and progenitor cells (HSPCs), the scientists engineered these cells to differentiate into B lymphocytes that continuously secrete therapeutic proteins. In preclinical models, this approach led to durable expression of antibodies in vivo, with protein levels maintained over months following a single intervention.

The strategy builds on advances in gene-editing technologies and stem cell biology. Unlike traditional protein replacement therapies that depend on external manufacturing and delivery, this method leverages the body’s own cellular machinery to produce proteins internally, potentially reducing treatment burden and improving consistency of therapeutic exposure.

Early applications described in the study include the production of anti-influenza antibodies and other candidate therapeutics. Researchers noted that the modified HSPCs engrafted in the bone marrow and gave rise to functional B cells capable of antigen-specific responses, suggesting potential for both prophylactic and therapeutic use.

Experts caution that while the results are promising, the approach remains in early stages of development. Key questions about long-term safety, immune tolerance, and scalability in humans require further investigation before clinical translation can be considered.

The study was conducted by researchers affiliated with multiple institutions, though specific author details and funding sources were not included in the initial release. The findings were published as a peer-reviewed article in Science, with a preprint version previously made available through bioRxiv in January 2026.

Ongoing work aims to optimize the gene-editing precision, assess durability across different animal models, and evaluate the platform’s applicability to a broader range of proteins, including enzymes for metabolic disorders and cytokines for immune modulation.

If successful in human trials, this technology could shift the paradigm for treating chronic conditions that require lifelong protein therapy, offering a one-time intervention with effects lasting years or even a lifetime.